Dr. Haley has over thirty years of experience in biochemical research in the fields of endocrinology, oncology, signal transduction and pharmacology, in which he has published over 50 manuscripts. Dr. Haley obtained B.Sc. cum laude in Chemistry from Tufts University, Medford, MA and a Ph.D. in Molecular Endocrinology from the Howard Florey Institute for Experimental Physiology and Medicine, Melbourne University, Australia. He served as a Research Fellow at the Imperial Cancer Research Fund (London) and at the Ludwig Institute for Cancer Research (London). He currently holds the position of Senior Research Director at OSI Pharmaceuticals/Astellas, and his group is focused on drug target pathway identification, validation and biomarker discovery through a scientific understanding of epithelial-mesenchymal transition and cancer recurrence. OSI Pharmaceuticals/Astellas is committed to discovering, developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for cancer patients worldwide. Tarceva is an EGFR-targeted therapy proven to significantly prolong survival in second-line NSCLC as a single agent. The research and development pipeline consists of novel molecularly targeted anti-cancer agents focused on signal transduction pathways involved in cell proliferation, apoptosis and angiogenesis using the science of epithelial-mesenchymal transition.
Abstracts this author is presenting: